Relief Therapeutics Holding AG (RLFTF)

[tcm55]

I see RLF-100 finally mentioned. Yes RLF had the 'right' to fund further formulations but I think Rod is sticking with the IV RLF-100 FORMULATION THAT WAS USED DURING THE PHASE 2B/3 CT.

THE INHALERS are in Phase 2 CTs. New formulations will need Trial.

IMO it's GEM trying to kick the mule and dangle more carrots to these shysters'. Its a deal by 5-24 or?
Max set @$35 for BRPA deal? Minimum is $10. NRX-101, LOL. Sold my few brpa.


BUTTTT!


On September 21, 2020, NeuroRx announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of RLF-100 (aviptadil acetate) (now reformulated as ZYESAMITM), an FDA Fast Track-designated, investigational, precommercial drug for COVID-19 related respiratory failure (the “NeuroRx COVID-19 Drug”). The partnership affords Relief Therapeutics the right to fund all formulations and clinical development of aviptadil for treatment of respiratory disease, in exchange for a predetermined share of profits. See the section titled “Business of NeuroRx — Summary of NeuroRx Material In-licensing Obligations — Aviptadil/ZYESAMI — Binding Collaboration Agreement with Relief Therapeutics — Division of Profits” for more information. NeuroRx is also developing NRX-100/101, an FDA Breakthrough Therapy-designated, investigational, precommercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior (the “NeuroRx Antidepressant Drug Regimen”).

https://ih.advfn.com/stock-market/NASDAQ/big-rock-partners-acquis-BRPA/stock-news/85169110/registration-statement-for-securities-to-be-issued